Glucagon-like Peptide 1 Global Market Report 2025

Glucagon-like Peptide 1 Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glucagon-like peptide 1 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description:

Where is the largest and fastest growing market for glucagon-like peptide 1 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glucagon-like peptide 1 market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope

Markets Covered:1) By Product: Trulicity; Ozempic; Victoza; Rybelsus; Other Types

2) By Route of Administration: Oral; Parenteral; Other Routes

3) By End-Users: Hospitals; Specialty Clinics; Other End Users

Subsegments:

1) By Trulicity: Injection (pre-filled pen); Dosage forms (0.75 mg, 1.5 mg, etc.)

2) By Ozempic: Injection (pre-filled pen); Dosage forms (0.5 mg, 1 mg, etc.)

3) By Victoza: Injection (pre-filled pen); Dosage forms (1.2 mg, 1.8 mg, etc.)

4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)

5) By Other Types: Experimental formulations; Combination products with other medications; Alternative delivery systems

Companies Mentioned: Novo Nordisk AS; Sanofi SA; Eli Lilly and Co; AstraZeneca plc; Pfizer Inc

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.


1. Executive Summary
2. Glucagon-like Peptide 1 Market Characteristics
3. Glucagon-like Peptide 1 Market Trends And Strategies
4. Glucagon-like Peptide 1 Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market
5. Global Glucagon-like Peptide 1 Growth Analysis And Strategic Analysis Framework
5.1. Global Glucagon-like Peptide 1 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Glucagon-like Peptide 1 Market Growth Rate Analysis
5.4. Global Glucagon-like Peptide 1 Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Glucagon-like Peptide 1 Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Glucagon-like Peptide 1 Total Addressable Market (TAM)
6. Glucagon-like Peptide 1 Market Segmentation
6.1. Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Trulicity
Ozempic
Victoza
Rybelsus
Other Types
6.2. Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Routes
6.3. Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Other End Users
6.4. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Trulicity, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injection (pre-filled pen)
Dosage forms (0.75 mg, 1.5 mg, etc.)
6.5. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Ozempic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injection (pre-filled pen)
Dosage forms (0.5 mg, 1 mg, etc.)
6.6. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Victoza, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injection (pre-filled pen)
Dosage forms (1.2 mg, 1.8 mg, etc.)
6.7. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Rybelsus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral tablet (3 mg, 7 mg, 14 mg)
6.8. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Experimental formulations
Combination products with other medications
Alternative delivery systems
7. Glucagon-like Peptide 1 Market Regional And Country Analysis
7.1. Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Glucagon-like Peptide 1 Market
8.1. Asia-Pacific Glucagon-like Peptide 1 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Glucagon-like Peptide 1 Market
9.1. China Glucagon-like Peptide 1 Market Overview
9.2. China Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Glucagon-like Peptide 1 Market
10.1. India Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Glucagon-like Peptide 1 Market
11.1. Japan Glucagon-like Peptide 1 Market Overview
11.2. Japan Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Glucagon-like Peptide 1 Market
12.1. Australia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Glucagon-like Peptide 1 Market
13.1. Indonesia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Glucagon-like Peptide 1 Market
14.1. South Korea Glucagon-like Peptide 1 Market Overview
14.2. South Korea Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Glucagon-like Peptide 1 Market
15.1. Western Europe Glucagon-like Peptide 1 Market Overview
15.2. Western Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Glucagon-like Peptide 1 Market
16.1. UK Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Glucagon-like Peptide 1 Market
17.1. Germany Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Glucagon-like Peptide 1 Market
18.1. France Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Glucagon-like Peptide 1 Market
19.1. Italy Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Glucagon-like Peptide 1 Market
20.1. Spain Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Glucagon-like Peptide 1 Market
21.1. Eastern Europe Glucagon-like Peptide 1 Market Overview
21.2. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Glucagon-like Peptide 1 Market
22.1. Russia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Glucagon-like Peptide 1 Market
23.1. North America Glucagon-like Peptide 1 Market Overview
23.2. North America Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Glucagon-like Peptide 1 Market
24.1. USA Glucagon-like Peptide 1 Market Overview
24.2. USA Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Glucagon-like Peptide 1 Market
25.1. Canada Glucagon-like Peptide 1 Market Overview
25.2. Canada Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Glucagon-like Peptide 1 Market
26.1. South America Glucagon-like Peptide 1 Market Overview
26.2. South America Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Glucagon-like Peptide 1 Market
27.1. Brazil Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Glucagon-like Peptide 1 Market
28.1. Middle East Glucagon-like Peptide 1 Market Overview
28.2. Middle East Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Glucagon-like Peptide 1 Market
29.1. Africa Glucagon-like Peptide 1 Market Overview
29.2. Africa Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Glucagon-like Peptide 1 Market Competitive Landscape And Company Profiles
30.1. Glucagon-like Peptide 1 Market Competitive Landscape
30.2. Glucagon-like Peptide 1 Market Company Profiles
30.2.1. Novo Nordisk AS Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Eli Lilly and Co Overview, Products and Services, Strategy and Financial Analysis
30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
31. Glucagon-like Peptide 1 Market Other Major And Innovative Companies
31.1. Boehringer Ingelheim International GmbH
31.2. F Hoffmann-La Roche Ltd
31.3. Bristol-Myers Squibb Company
31.4. Baxter
31.5. Hikma Pharmaceuticals plc
31.6. Zealand Pharma A/S
31.7. Intarcia Therapeutics Inc.
31.8. GlaxoSmithKline plc
31.9. Jiangsu Hansoh Pharmaceutical Group Co Ltd
31.10. Shanghai Benemae Pharmaceutical Corporation
31.11. Adocia
31.12. Biocon
31.13. Hanmi Pharmaceutical Co Ltd
31.14. Ligand Pharmaceuticals Incorporated
31.15. Advinus Therapeutics Ltd
32. Global Glucagon-like Peptide 1 Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Glucagon-like Peptide 1 Market
34. Recent Developments In The Glucagon-like Peptide 1 Market
35. Glucagon-like Peptide 1 Market High Potential Countries, Segments and Strategies
35.1 Glucagon-like Peptide 1 Market In 2029 - Countries Offering Most New Opportunities
35.2 Glucagon-like Peptide 1 Market In 2029 - Segments Offering Most New Opportunities
35.3 Glucagon-like Peptide 1 Market In 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings